We carried out a retrospective study in patients who underwent EGFR mutation testing and pretreatment with FDG-PET/CT in NSCLC, and we discuss the relationships between 18F-FDG uptake, clinical features, and EGFR mutation status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.